Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

27.72 +0.20 (+0.73%)
Streaming Delayed Price Updated: 3:09 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 536,323
Open 27.43
Bid (Size) 27.71 (1)
Ask (Size) 27.73 (4)
Prev. Close 27.52
Today's Range 27.32 - 27.82
52wk Range 16.10 - 41.94
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary
Via Stocktwits
Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug
Goldman Sachs cited Apellis’ 6% quarterly injection growth for Syfovre and potential market upside from Empaveli’s newly approved indications in C3G and IC-MPGN, despite recent revenue headwinds from... 
Via Stocktwits

Performance

YTD
-16.4%
-16.4%
1 Month
+47.8%
+47.8%
3 Month
+64.1%
+64.1%
6 Month
+1.1%
+1.1%
1 Year
-30.4%
-30.4%

More News

Read More
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday
Via Benzinga
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss
Via Chartmill
Earnings Scheduled For July 31, 2025
Via Benzinga
Earnings Scheduled For May 7, 2025
Via Benzinga
Apellis Pharmaceuticals's Earnings Outlook
Via Benzinga
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio
Via Benzinga
Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals
Via Stocktwits
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)
Via Benzinga
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Via Benzinga
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.; Sobi
Via GlobeNewswire
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts
Via Benzinga
Why Apellis Pharmaceuticals Wilted on Wednesday
Via The Motley Fool
Topics Earnings
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Via Benzinga

Frequently Asked Questions

Is Apellis Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Apellis Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Apellis Pharmaceuticals, Inc. - Common Stock trade on?
Apellis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock is APLS on the Nasdaq Stock Market
What is the current price of Apellis Pharmaceuticals, Inc. - Common Stock?
The current price of Apellis Pharmaceuticals, Inc. - Common Stock is 27.72
When was Apellis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Apellis Pharmaceuticals, Inc. - Common Stock was at 08/26/25 03:09 PM ET
What is the market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock is 3.23B
How many shares of Apellis Pharmaceuticals, Inc. - Common Stock are outstanding?
Apellis Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.